Jubilant Biosys Limited announces the appointment ofMr. Giuliano Perfetti as Chief Executive Officer
September 07, 2021, Bengaluru, India - Today, Jubilant Biosys
Limited announced the appointment of Giuliano Perfetti as its Chief
Executive Officer.
Mr. Perfetti has more than 20 years of experience across diverse
businesses and global markets with expertise in Strategy, Sales,
Marketing and Business Development. He has led business
transformation and expansion programs working in reputed names
including Accenture and Astrazeneca among others. Prior to joining
Jubilant Biosys, Mr. Perfetti was associated with Fabbrica
Italiana Sintetici (F.I.S) as Chief Commercial Officer and was responsible for strategizing andexecuting the company’s growth plan and ramping up the global scale-up and commercial
service business.
Commenting on his joining, Mr. Shyam S Bhartia, Chairman and Mr Hari S Bhartia CoChairman and Managing Director Jubilant Pharmova said “Jubilant Biosys is delighted tohave Giuliano come on board as we make rapid progress in expanding our drug discovery
services and CDMO business through investments in infrastructure and new capacity.”“I am thrilled to be joining the Jubilant Bhartia Group at such a pivotal time of growth andinvestment bringing a fully integrated offering from Drug Discovery to Development andCommercial Production” said Mr. Giuliano Perfetti on his appointment.
About Jubilant Biosys Limited
Jubilant Biosys, a subsidiary of Jubilant Pharmova Limited, an integrated global
pharmaceutical company, has presence in Bengaluru and Noida in India. Jubilant Biosys
offers contract research & development services for global pharmaceutical innovators.
Jubilant Biosys has demonstrated expertise in functional services in chemistry includingcomputational, medicinal/ synthetic chemistry, PR&D and GMP scale-up capabilities up tophase II. Services in biology include structural biology, in-vitro biology, DMPK, in-vivo
pharmacology and Toxicology. Further, Jubilant Biosys has integrated discovery expertisewith a track record of working on over 80 programs in multiple therapeutic areas including
but not limited to Oncology, Metabolic Disorders, Pain & Inflammation, CNS and expanding
into Rare Diseases.
For more info: www.jubilantbiosys.com
for Business Development Contact:
Ravichandran S
bd@jubilantbiosys.com

About Jubilant Pharmova Limited
Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company engaged
in pharmaceuticals, contract research and development services and proprietary novel drugs
businesses. Pharmaceuticals business through Jubilant Pharma Limited Singapore (JPL) isengaged in manufacturing and supply of Radiopharmaceuticals with a network of 48 radiopharmacies in the US, Allergy Therapy Products, Contract Manufacturing of Sterile Injectibles
and Non-sterile products, APIs and Solid Dosage Formulations through six USFDA approved
manufacturing facilities in the US, Canada and India. Jubilant Biosys Limited provides
Contract Research and Development Services through three world class research centres inBangalore, Noida and Greater Noida in India. Jubilant Therapeutics is involved in Proprietary
Novel Drugs business and is an innovative biopharmaceutical company developing
breakthrough therapies in the area of oncology and auto-immune disorders. Jubilant
Pharmova Limited has a team of around 5,800 multicultural people across the globe. TheCompany is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals companies
globally. For more information, please visit: www.jubilantpharmova.com.
Available on